InstantWhyThe deal
Seeking Alpha reports that a FOXO Technologies unit will acquire four U.S. blood collection centers from a Grifols subsidiary. The report did not disclose financial terms or identify which FOXO unit is making the purchase. Neither company has independently confirmed the transaction.
Why it matters
FOXO has been building a lab network to commercialize its longevity diagnostics, and owning collection sites rather than relying on third-party draws cuts costs and speeds sample turnaround. For Grifols, shedding the centers suggests continued portfolio rationalization after the Spanish plasma giant faced debt and governance pressure over the past year.
Deal context
FOXO Technologies focuses on epigenetic biomarker analysis, selling life insurance underwriting tools and consumer longevity tests that measure biological age from blood samples. Grifols operates a global network of plasma donation centers and has been under investor scrutiny since short-seller allegations in early 2024 questioned its accounting, prompting management changes and asset review. The company has been working to reduce leverage and streamline operations.
What has to happen next
The transaction still requires regulatory approval and closing conditions typical of healthcare facility transfers. FOXO will need to integrate the centers into its existing lab workflow, and the deal's success depends on sample volume and whether the company can convert collection capacity into revenue from insurers and consumers.
- ✓Detected and written at 2026-07-29 13:23
- ✓First reported by Seeking Alpha
- ✓Written from public facts in our own words — never a copy
- ✓Published as fast as possible; our team holds editorial responsibility
Sources
- Seeking Alpha — Market Currents: https://seekingalpha.com/news/4620336-foxo-unit-to-acquire-four-u-s-blood-collection-centers-from-grifols-subsidiary?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
More stories
InstantWhyeBay agrees to pay $55.7 million to settle cyberstalking lawsuit
InstantWhyLaw firm opens securities investigation into Fulcrum Therapeutics
InstantWhy